Mink Therapeutics shares fall 19.28% in after-hours following publication of case study in Nature's Oncogene.

Mink Therapeutics, Inc. surged 19.28% in after-hours trading, following the publication of a case study in Nature's Oncogene journal showing a metastatic testicular cancer patient achieved complete remission and remained disease-free for over two years after receiving agenT-797 cell therapy. The company is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf iNKT cell therapies for cancer treatment.